Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Oslo Bors  >  Photocure ASA    PHO   NO0010000045

Delayed Quote. Delayed  - 08/26 04:25:05 pm
43.9 NOK   -2.44%
08/24 PHOTOCURE : Hexvix® marketing authorization approval in Australia
08/23 PHOTOCURE : Presentation of the second quarter 2016 results and Hexv..
08/23 PHOTOCURE : Results for second quarter and first half year 2016
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Oslo Bors
08/22/2016 08/23/2016 08/24/2016 08/25/2016 08/26/2016 Date
50.5(c) 46.4(c) 45.5(c) 45(c) 43.9(c) Last
23 704 77 265 82 565 55 137 55 023 Volume
-1.94% -8.12% -1.94% -1.10% -2.44% Change
More quotes
Financials ( NOK)
Sales 2016 146 M
EBIT 2016 -21,2 M
Net income 2016 -11,9 M
Debt 2016 108 M
Yield 2016 -
Sales 2017 169 M
EBIT 2017 5,49 M
Net income 2017 7,35 M
Debt 2017 92,6 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 121,94
EV / Sales2016 7,22x
EV / Sales2017 6,14x
Capitalization 944 M
More Financials
Company
Photocure ASA engages as a pharmaceutical company, which engages in the provision of photodynamic diagnosis and treatment.It operates through Commercial Franchise and Development Portfolio segments.The Commercial Franchise segment includes Hexvix/Cysview products and is broken down into own and... 
Sector
Pharmaceuticals
Calendar
11/15Earnings Release
More about the company
Surperformance© ratings of Photocure ASA
Trading Rating : Investor Rating :
More Ratings
Latest news on PHOTOCURE ASA
08/24 PHOTOCURE : Hexvix® marketing authorization approval in Australia
08/23 PHOTOCURE : Results for second quarter and first half year 2016
08/23 PHOTOCURE : Presentation of the second quarter 2016 results and Hexvix/Cysview u..
08/23 PHOTOCURE ASA : Results for second quarter and first half year 2016
08/18PHOTOCURE ASA : half-yearly earnings release
08/17 PHOTOCURE ASA : Presentation of the second quarter 2016 results and Hexvix/Cysvi..
08/16 PHOTOCURE : Disclosure of Large Shareholding
08/11 PHOTOCURE ASA : Cysview® granted fda approval of new prefilled syringe product p..
08/02 PHOTOCURE ASA : New meta-analysis shows that Blue Light Cystoscopy with Hexvix®/..
08/02 PHOTOCURE : New meta-analysis shows that BLC with Hexvix®/Cysview® significantly..
More news
Sector news : Pharmaceuticals - NEC
08/27 Stada shareholder AOC pushes through board reshuffle
08/27 ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Pharmaceuticals - NEC
Advertisement
Chart PHOTOCURE ASA
Duration : Period :
Photocure ASA Technical Analysis Chart | PHO | NO0010000045 | 4-Traders
Full-screen chart
Technical analysis trends PHOTOCURE ASA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 51,0  NOK
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kjetil Hestdal President, Chief Executive Officer & Media Contact
Bente-Lill Bjerkelund Romøren Chairman
Erik Dahl Chief Financial Officer & IR Contact
Inger Ferner Heglund Vice President-Research & Development
Xavier Denis Yon Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PHOTOCURE ASA4.77%114
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-12.84%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-10.83%210 234
ASTRAZENECA PLC7.33%173 797
More Results